thebench.bio #1 Ecosystem for the Bio-Tech Industry

Clinical Daily Summary

Clinical Daily Summary: What Happened on November 11, 2026

Beam’s sickle cell therapy meets its pivotal-trial goal

Amgen’s Sjögren’s disease results and J&J’s bipolar mania data add two Phase 3 updates.

  • Updated
  • Read from 13 articles, 6 publications
  • B N B

Today in brief

Beam Therapeutics said risto-cel met BEACON’s primary endpoint, which required 12 months without severe pain crises.12 Amgen said both dazodalibep regimens reduced systemic disease activity versus placebo in a Phase 3 Sjögren’s disease trial.3

Johnson & Johnson reported Phase 3 success for Caplyta in manic episodes of bipolar I disorder and plans to seek approval for that use.4

Beam says risto-cel met its sickle cell trial endpoint

Beam said risto-cel met the primary endpoint in BEACON, an open-label study in severe sickle cell disease.1 The endpoint required at least 12 consecutive months without severe vaso-occlusive crises, assessed independently.12 At the October 20 data cutoff, 39 adults and 10 adolescents had received treatment, and 31 had completed the follow-up required for the endpoint.12

Beam also said the trial met its primary safety and secondary efficacy endpoints, including a measure of time without hospitalization for severe crises.12 Beam said it could submit an application to the FDA as soon as late 2026 and plans to present detailed pivotal results in 2027.12

Amgen’s two dazodalibep regimens hit the Phase 3 endpoint

In OASIZ-301, a Phase 3 trial of 648 people with Sjögren’s disease, both dazodalibep regimens reduced systemic disease activity more than placebo at Week 48.3 The mean disease-activity score fell 5.6 points with 1,500 milligrams every four weeks, versus 3.8 points with placebo.3 With 3,000 milligrams every 12 weeks, the score fell 5.2 points.3

The every-four-weeks regimen also improved patient-reported dryness versus placebo, and treated patients had larger increases in stimulated salivary flow.3 Treatment effects appeared by Week 4 and continued through Week 48.3 Nasopharyngitis, urinary tract infection, hypertension and infusion reactions were reported more often with dazodalibep, generally at mild or moderate severity.3 Serious adverse events and treatment discontinuations due to adverse events were balanced between groups, while malignancy rates were low and similar.3

Amgen is also running a Phase 3 study in patients with high symptom burden but low systemic disease activity, along with a long-term extension study.3

Also worth knowing

  • PepGen reported mean muscle splicing correction of 46.5% at Week 13 in six people with myotonic dystrophy type 1, alongside improvements in myotonia and grip strength. The company expects additional dose-cohort results in the first half of 2027.56

  • Lipocine dosed the first participant in BLOOM, a placebo-controlled Phase 3 trial of a 48-hour, at-home oral brexanolone treatment for postpartum depression, with results expected in the second half of 2027.7

  • Natera and Incyte will test Incyte’s investigational bispecific INCA33890 in a Phase 2 colorectal cancer study, using Natera’s Signatera blood test to monitor minimal residual disease and help determine treatment eligibility.8

  • Nimbus Therapeutics began first-in-human dosing of NDI-225673, a selective SIK2 inhibitor for immune-mediated inflammatory diseases. Preclinical findings have not established whether the drug will have clinical benefit.9

  • B

    ImvivaBio said 7 of 8 evaluable patients with refractory systemic lupus erythematosus remained in remission 12 months after receiving its dual-target CAR-T therapy CTA313 in Phase 1.1011

  • N

    A study in non-small-cell lung cancer linked a computational measure of tumor TROP2 distribution to longer progression-free survival with datopotamab deruxtecan, but not with docetaxel.12

  • B

    An unnamed biotech reported that its experimental treatment was associated with an 87% decrease in treated bleeding rates in one Phase 2 dosing group for Glanzmann thrombasthenia.13

Also published